Codexis Posts Q2 2026 Revenue of $14.9M, Reaffirms Full-Year Outlook, and Pushes Cash Runway to 2028

summarizeSummary

Codexis reported Q2 2026 revenue of $14.9 million, reaffirmed full-year guidance, and extended its cash runway to 2028 following a $25 million equity raise. The update highlights progress toward commercializing its ECO Synthesis platform and removes near-term funding risk.

check_boxKey Events · Earnings and Guidance · CDXS

• Q2 Revenue Beats Pre-Announced Floor

  Revenue of $14.9 million exceeded the pre-announced minimum of $14.8 million, driven by higher product revenue from new customer product launches.

• Cash Runway Extended to 2028

  Pro forma cash of approximately $80 million after the July equity raise funds operations through the end of 2028, including the GMP facility build-out.

• Full-Year Guidance Reiterated

  Management reaffirmed 2026 revenue guidance of $72–$76 million and gross margin in the high 60% range, signaling confidence in the second-half pipeline.

• GMP Facility and FDA Engagement Advance

  The company plans to submit a building permit application for its ECO GMP Manufacturing Center in H2 2026 and expects an FDA meeting in Q4 2026 to discuss product quality and comparability.

auto_awesomeAnalysis · CDXS · Industrial Applications And Services

Second-quarter revenue came in at $14.9 million, edging past the pre-announced floor of $14.8 million, while full-year revenue guidance of $72–$76 million was reiterated. A $25 million equity raise in July lifted the pro forma cash balance to roughly $80 million, extending the runway through the end of 2028 and eliminating near-term liquidity concerns. That funding also supports construction of a GMP manufacturing facility essential for commercializing the ECO Synthesis platform. Looking ahead, catalysts include a building permit application and an FDA meeting in Q4 2026, both of which could help de-risk the regulatory path for enzymatically synthesized RNA therapeutics.